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were treated with BMS or DES. Multiple logistic regression 
analyses were performed to identify variables associated 
with stent choice. Bivariate analyses showed that NYHA 
class, number of diseased vessels, previous percutaneous 
coronary intervention, smoking, diabetes, and the treating 
hospital were associated with stent type. After correcting for 
other associations the treating hospital remained significant-
ly associated with stent type in the stable CAD population.
Conclusions This study showed that several factors were 
associated with stent choice. While patients generally ap-
pear to receive the most optimal stent given their clinical 
characteristics, stent choice seems partially determined by 
the treating hospital, which may lead to differences in long-
term outcomes.
Abstract
Aim Variations in treatment are the result of differences in 
demographic and clinical factors (e.g. anatomy), but physi-
cian and hospital factors may also contribute to treatment 
variation. The choice of treatment is considered important 
since it could lead to differences in long-term outcomes. 
This study explores the associations with stent choice: i.e. 
drug-eluting stent (DES) versus bare-metal stents (BMS) 
for Dutch patients diagnosed with stable or unstable coro-
nary artery disease (CAD).
Methods & results Associations with treatment decisions 
were based on a prospective cohort of 692 patients with 
stable or unstable CAD. Of those patients, 442 patients 
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Introduction
Despite improvement in the prognosis of patients with car-
diovascular disease (CVD) it still remains the second lead-
ing cause of death across the Western world and one of the 
major causes of disability [1]. For many years patients with 
coronary artery disease (CAD), the most frequent type of 
CVD, were treated mainly with percutaneous coronary 
intervention (PCI), coronary artery bypass grafting (CABG) 
or medication only. Both revascularisations reduce the 
incidence of death and myocardial infarction (MI) in CAD 
patients compared with no treatment, but most patients 
are now treated with PCI. In 2012 approximately 39,000 
PCIs were performed in the Netherlands [2]. Originally a 
PCI was performed with an expanding balloon; however, 
nowadays patients are often treated with a bare-metal stent 
(BMS) or drug-eluting stent (DES). DES reduces resteno-
sis compared with BMS (8.4 versus 20.9 %) [3]. However, 
patients treated with DES, especially the early-generation, 
might have a higher chance of developing very late stent 
thrombosis (0.7 versus 0.1 %) [3]. Both types of stents have 
pros and cons; decisions should be based on what is con-
sidered appropriate for a patient since the choice of stent 
type may have impact on long-term outcomes. Variations 
in treatment are the result of differences in patient char-
acteristics and clinical factors (e.g. anatomy) but previous 
studies have shown that physician and hospital factors may 
contribute to treatment variation. In the UK, stent choice 
was associated with the operator and the treating hospital 
[4]. Tu et al. [5] have shown that the physician performing 
the diagnostic catheterisation and the treating hospital were 
strong independent predictors of the type of revascularisa-
tion (CABG versus PCI) in Canada. Furthermore, the type 
of stent was also determined by the type of payer (e.g. Med-
icaid, private insurance) [6]. Of course, these results may be 
expected to be healthcare system specific and do not apply 
for Dutch patients, since the Netherlands has a centrally 
publicly funded healthcare system.
This study will explore the associations with stent choice 
(DES or BMS) for Dutch patients diagnosed with stable or 
unstable CAD focusing on variation due to clinical factors 
and treating hospital.
Methods
Study design
Treatment variation of patients with stable or unstable CAD 
was explored through analysing data from the Circulating 
Cells prospective cohort study, which has the aim of discov-
ering markers that identify patients who are at an increased 
risk of developing a cardiovascular event. In this multicen-
tre study, patients undergoing coronary angiography were 
included if they had known or suspected stable or unstable 
CAD; specific diagnoses included unstable angina and non-
ST-elevation MI (NSTEMI) [7].
Treatment
Patients undergoing coronary angiography were asked 
to participate in the study. Data were collected regarding 
patient characteristics, test results and treatment decisions. 
Patients who were treated with a PCI received a BMS, DES, 
drug-eluting balloon angioplasty or standard balloon angio-
plasty. The aim of this study is to examine the factors that 
are associated with stent choice (DES vs. BMS), meaning 
that patients treated solely with drug-eluting balloon angio-
plasty or standard balloon angioplasty are excluded from the 
analyses. Stent choice for DES was defined as a PCI with at 
least one DES, including patients treated with only DES but 
also patients treated with DES in combination with BMS, 
drug-eluting balloon angioplasty or standard balloon angio-
plasty. Stent choice for BMS was defined as a PCI with only 
BMS such that patients treated with BMS in combination 
with balloon angioplasty or DES are excluded.
Data and statistical analyses
Choice of stent type (DES or BMS) was compared between 
patient subgroups, determined by diagnosis. The follow-
ing baseline characteristics were also collected during the 
study: age, gender, body mass index (BMI), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), thromboly-
sis in myocardial infarction (TIMI) score for unstable CAD 
patients, New York Heart Association (NYHA) class, num-
ber of diseased vessels (50–99 % stenosis), cardiac history 
(previous heart failure, previous MI, previous PCI, and pre-
vious CABG), non-cardiac history (cerebrovascular acci-
dent (CVA) or transient ischaemic attack (TIA), pulmonary 
disease, peripheral vessel disease (PVD), and renal failure), 
and CVD risk factors (diabetes mellitus, hypertension, 
hyperlipidaemia, smoking, and pack-years (tobacco)).
Multiple imputation was used to prevent patients from 
being excluded from the analyses due to missing values. 
Baseline characteristics (SBP, DBP, BMI, NYHA class, pre-
vious heart failure, previous MI, CVA or TIA, pulmonary 
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All patients after imputation Patients with stable CAD Patients with unstable CAD p valuea
Mean SD Nb Mean SD Nb Mean SD Nb
Baseline characteristics
Age 62.72 10 442 62.96 10 358 61.71 11 84 0.319
Male (%) 72 % 442 73 % 358 68 % 84 0.354
SBP (mmHg) 135 19 442 135 19 358 134 21 84 0.748
DBP (mmHg) 77 11 442 77 11 358 79 11 84 0.273
BMI (kg/m2) 28 4 442 28 4 358 27 4 84 0.266
TIMI scorec
1 8 % 83 8 % 83
2 18 % 83 18 % 83
3 30 % 83 30 % 83
4 28 % 83 28 % 83
5 12 % 83 12 % 83
6 + 7 4 % 83 4 % 83
Number of diseased vessels (50–99 %) 0.077
1 44 % 442 46 % 358 36 % 84
> 1 56 % 442 54 % 358 64 % 84
NYHA p < 0.001
NYHA I 73 % 442 73 % 358 76 % 84
NYHA II 18 % 442 20 % 358 7 % 84
NYHA III 6 % 442 7 % 358 4 % 84
NYHA IV 2 % 442 0 % 358 13 % 84
Cardiac history (%)
Previous heart failure 2 % 442 2 % 358 1 % 84 0.542
Previous MI 31 % 442 33 % 358 23 % 84 0.066
Previous PTCA 33 % 442 35 % 358 26 % 84 0.116
Previous CABG 7 % 442 8 % 358 5 % 84 0.369
Non-cardiac history (%)
CVA/TIA 8 % 442 6 % 358 14 % 84 0.017
Pulmonary disease 11 % 442 10 % 358 14 % 84 0.242
Peripheral vessel disease 13 % 442 13 % 358 14 % 84 0.684
Renal failure 3 % 442 4 % 358 1 % 84 0.25
Risk factors (%)
Diabetes mellitus 21 % 442 22 % 358 20 % 84 0.764
Hypertension 66 % 442 67 % 358 60 % 84 0.189
Hyperlipidaemia 68 % 442 70 % 358 60 % 84 0.057
Current smokers 19 % 442 16 % 358 32 % 84 0.001
Pack yearsd 19.7 18 442 19.2 18.1 358 21.9 22.1 84 0.302
Diagnosis (%)
Stable angina 81 % 442
Unstable angina 10 % 442
NSTEMI 9 % 442
Treatment/stent choice 0.736
DES 66 % 442 66 % 358 68 % 84
BMS 34 % 442 34 % 358 32 % 84
Hospital
I 29 % 442 28 % 358 37 % 84
II 22 % 442 24 % 358 13 % 84
III 18 % 442 14 % 358 37 % 84
IV 30 % 442 34 % 358 13 % 84
BMI body mass index, CABG coronary artery bypass graft, CVA cerebrovascular accident, DBP diastolic blood pressure, MI myocardial infarction, 
NA not applicable, NSTEMI non ST elevation myocardial infarction, NYHA New York heart association, PTCA percutaneous transluminal coronary 
angioplasty, SBP systolic blood pressure, TIA transient ischaemic attack, TIMI thrombolysis in myocardial infarction.
aStable versus unstable.
bNumber of patients on which the analyses were based.
cOnly reported for unstable angina and NSTEMI.
dNumber of packs per day multiplied with years of smoking.
Table 1 Baseline characteristics
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Of the 442 patients, 66 % were treated with one or more 
DES. Bivariate analyses (Table 2) showed that NYHA class, 
number of diseased vessels, previous PCI, smoking, diabe-
tes and the treating hospital were significantly associated 
with stent choice for a patient. The frequency of DES use 
varied widely (50–99 %) between the four hospitals, consid-
ering the total population. The variation in stent choice was 
larger in the unstable patient group (45–100 %).
All multivariate analyses (Table 3) showed that patients 
with diabetes had a significantly higher chance of receiv-
ing DES. The use of DES versus BMS in the stable CAD 
population was not only associated with diabetes but also 
with the treating hospital, smoking status, and previous PCI. 
Patients treated in hospital II or III, patients having diabetes, 
and patients with a previous PCI had a higher chance of 
being treated with DES. Patients treated in hospital I and 
patients who were current smokers had a lower chance of 
being treated with DES.
Discussion
This study explored the factors associated with stent choice 
for Dutch patients diagnosed with stable or unstable CAD. 
Various factors are associated with the frequency of DES 
use, including diabetes, previous PCI, number of diseased 
vessels, NYHA class, smoking and the treating hospital.
Patients requiring a PCI were in most cases treated with 
at least one DES (66 %), which is in line with the guidelines 
that suggest that patients with stable CAD should receive a 
DES if there is no contraindication of prolonged dual anti-
platelet therapy [8]. Furthermore, DES is recommended 
over BMS in NSTEMI or unstable angina patients with dia-
betes [9]. Since patients with diabetes have a higher reste-
nosis risk than patients without diabetes, DES is considered 
the most optimal treatment for these patients since DES 
reduces restenosis compared with BMS. Consequently, dia-
betes was significantly associated with stent choice in this 
study. Patients who have been treated before with a PCI 
were also more likely to receive DES (76 %); these patients 
have a higher risk of developing restenosis and thus DES 
was preferred. Patients with multi-vessel disease (73 % 
DES) and patients with a high NYHA class (range I–IV: 
62–90 % DES) were significantly more frequently treated 
with DES. Studies suggest that patients with multi-vessel 
disease should be treated with CABG or PCI using DES 
since these interventions have shown to be more effective 
than BMS [10]. Patients currently smoking were less often 
treated with DES.
These clinical factors can be considered as legitimate 
leading to variation in stent choice. However, 19 % of the 
variation in stent choice was explained by these factors in 
the stable CAD population. Beside clinical factors, other 
disease, PVD, renal failure, diabetes mellitus, hypertension, 
hyperlipidaemia, current smoker and pack-years) were miss-
ing for less than 2 % of all cases except pack-years, which 
was missing for 14 % of all cases. These characteristics were 
imputed using predictive mean matching for scale variables. 
Five imputation sets were created with ten iterations, each 
using fully conditional specification in SPSS 22 (IBM Corp. 
Released 2013. IBM SPSS Statistics for Windows, Version 
22.0. Armonk, NY: IBM Corp). Age, gender, previous PCI, 
previous CABG, and diagnosis were only used as predic-
tors and not imputed since there were no missing values for 
these variables.
Differences between groups were tested using Chi-
squared analysis for categorical variables. Bivariate analy-
ses using logistic regression were performed to identify 
variables that were associated with stent type; stable and 
unstable CAD patients were analysed separately. Back-
wards selection was used to create the final multivariate 
model(s). P values lower than 0.05 were considered statis-
tically significant, although a higher threshold of 0.1 was 
used to select variables for the multivariate analysis. Asso-
ciations were discussed with clinical experts in order to see 
if the results make sense (face validity).
Results
In total, 714 patients were included in the Circulating Cells 
cohort, 22 of whom were excluded from the analyses since 
they did not have significant coronary atherosclerosis. The 
remaining 692 patients were included in three teaching hos-
pitals and one general hospital, and 477 patients were treated 
with PCI. Of those patients, 442 patients were treated with 
BMS or DES. Others were treated with a combination of 
BMS and balloon angioplasty (n = 4), drug-eluting balloon 
angioplasty or standard balloon angioplasty (n = 18) or miss-
ing (n = 13) and are excluded from the analysis. The number 
of patients treated per hospital (I–IV) was 130, 98, 81, and 
133, respectively. Table 1 presents the baseline demographic 
and angiographic characteristics of the included patients. 
The mean age of the cohort was 63 years and 72 % were 
male. The majority (81 %) of the patients were diagnosed 
with stable CAD (including silent ischaemia) after the coro-
nary angiography. There were three significant differences 
in characteristics of stable CAD (n = 358) and unstable CAD 
patients (n = 84). Stable CAD patients more often had a 
lower NYHA class, were less often current smokers and had 
less often experienced a CVA/TIA compared with unstable 
CAD patients.
In total 771 stents were used to treat 442 patients with 612 
target lesions. On average 1.385 target lesions were stented 
per patient (range 1–3), where 1.260 stents were used per 
lesion and 1.744 stents (range 1–6) per patient were used. 
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Table 2 Associations with therapeutic decision (DES vs BMS)
All patients Patients with stable CAD Patients with unstable CAD
DES (%)/ OR N p value DES (%)/ OR N p value DES (%)/ OR N p value
Overall 66 % 442 66 % 358 68 % 84
Diagnosis 0.558
Stable CAD 66 % 358
Unstable angina 63 % 46
NSTEMI 74 % 38
Hospital p < 0.001 p < 0.001 p < 0.001
1 50 % 130 52 % 99 45 % 31
2 64 % 98 66 % 87 55 % 11
3 99 % 81 98 % 50 100 % 31
4 64 % 133 65 % 122 55 % 11
Baseline characteristics
Age (years) 1.008 442 0.387 1.005 358 0.682 1.023 84 0.272
Gender 0.474 0.46 0.872
Male 67 % 318 67 % 261 68 % 57
Female 64 % 124 63 % 97 67 % 27
SBP (mmHg) 1.007 442 0.188 1.003 358 0.598 1.022 84 0.074
DBP (mmHg) 0.998 442 0.815 0.997 358 0.767 1.001 84 0.968
BMI (kg/m2) 1.038 442 0.128 1.049 358 0.08 0.994 84 0.912
TIMI scorea 0.085 0.085
1 71 % 7 71 % 7
2 80 % 15 80 % 15
3 48 % 25 48 % 25
4 83 % 23 83 % 23
5 60 % 10 60 % 10
6 + 7 100 % 3 100 % 3
NYHA p < 0.01 0.036 0.011
NYHA I 62 % 324 63 % 260 59 % 64
NYHA II 71 % 79 69 % 73 100 % 6
NYHA III & IV 90 % 39 88 % 25 93 % 14
Number of diseased 
vessels
p < 0.01 p < 0.01 0.102
1 58 % 196 58 % 166 57 % 30
> 1 73 % 246 72 % 192 74 % 54
Cardiac history
Previous heart failure 0.981 0.836 0.489
Yes 67 % 9 63 % 8 100 % 1
No 66 % 433 66 % 350 67 % 83
Previous MI 0.077 0.090 0.536
Yes 72 % 137 72 % 118 74 % 19
No 64 % 305 63 % 240 66 % 65
Previous PTCA p < 0.01 p < 0.01 0.271
Yes 76 % 148 76 % 126 77 % 22
No 61 % 294 60 % 232 65 % 62
Previous CABG 0.541 0.736 0.433
Yes 61 % 31 63 % 27 50 % 4
No 67 % 411 66 % 331 69 % 80
Non-cardiac history
CVA/TIA 0.748 0.682 0.924
Yes 69 % 35 70 % 23 67 % 12
No 66 % 407 66 % 335 68 % 72
Pulmonary disease 0.103 0.142 0.445
Yes 56 % 47 55 % 35 58 % 12
No 68 % 395 36 % 323 69 % 72
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After adding treating hospital to the regression analysis 
33 % of the variation in stent choice could be explained. The 
analyses showed that the frequency of DES use ranged from 
50–99 % of all patients across hospitals. This difference 
could result from a difference in patient case mix, despite 
the adjustment for many individual patient characteristics in 
the analyses. Furthermore, payment arrangements with stent 
manufacturers and budget constraints may have influenced 
the stent choice. Another potential reason, patient prefer-
ence, could have influenced the variation in stent choice. 
However, we expect this to be minimal since both interven-
tions can be considered to be equally invasive.
Implications
In general, patients receive the most optimal stent given 
their clinical characteristics. However, stent choice is also 
determined by the treating hospital, probably due to oper-
ator variation and availability and supply of resources. 
Variation should only occur due to demographic and angio-
graphic factors. When variation is due to factors other than 
demographics or angiography findings it could lead to less 
optimal stent choices and subsequently differences in long-
term outcomes.
potential reasons for treatment variation could exist due to: 
(1) the operator, (2) the availability and supply of resources, 
or (3) patient preferences. Considering operator variation, 
physicians use different methods to decide which stent is 
most suited for a particular patient. It is known that some 
physicians are believers of DES and some do not believe in 
the added value of DES compared with BMS, while BMS 
is less expensive. In several randomised clinical trials, DES 
has shown to be more effective than BMS for several indi-
cations (e.g. diabetes, long lesions). Some operators strictly 
follow the results of these trials and the guidelines while 
other operators also use DES for other indications with a 
high restenosis risk since guidelines do not provide recom-
mendations concerning the most optimal stent for every type 
of patient, although it is probably unrealistic to expect this. 
In our study, one hospital treated almost all patients with 
DES (99 %); probably DES was used also for ‘off-label’ 
indications. A Dutch report concluded that world-wide DES 
is used off-label in 47–81 % of the patients, leading to dif-
ferences in safety and clinical effectiveness [11]. The sec-
ond potential reason, availability and supply of resources, 
focuses on the hospital level. In our analyses, the treating 
hospital was significantly associated with stent choice even 
after correcting for clinical factors in the stable CAD group. 
Table 2 (continued)
All patients Patients with stable CAD Patients with unstable CAD
DES (%)/ OR N p value DES (%)/ OR N p value DES (%)/ OR N p value
PVD 0.086 0.124 0.445
Yes 56 % 57 56 % 45 58 % 12
No 68 % 385 67 % 313 69 % 72
Renal failure 0.059 0.126 0.144
Yes 43 % 14 46 % 13 0 % 1
No 67 % 428 67 % 345 69 % 83
Risk factors
Diabetes mellitus p < 0.001 p < 0.001 0.009
Yes 93 % 95 92 % 78 94 % 17
No 59 % 347 59 % 280 61 % 67
Hypertension 0.306 0.498 0.324
Yes 68 % 290 67 % 240 72 % 50
No 63 % 152 63 % 118 62 % 34
Hyperlipidaemia 0.943 0.427 0.144
Yes 66 % 302 65 % 252 74 % 50
No 67 % 140 69 % 106 59 % 34
Current smokers 0.037 0.066 0.246
Yes 57 % 85 55 % 58 59 % 27
No 69 % 357 68 % 300 72 % 57
Pack yearsb 1.001 442 0.898 1.000 358 0.974 1.002 84 0.877
BMI body mass index, CABG coronary artery bypass graft, CAD coronary artery disease, CVA cerebrovascular accident, DBP diastolic blood 
pressure, MI myocardial infarction, NA not applicable, NSTEMI non ST elevation myocardial infarction, NYHA New York heart association, 
PTCA percutaneous transluminal coronary angioplasty, PVD peripheral vessel disease, SBP systolic blood pressure, TIA transient ischaemic 
attack, TIMI thrombolysis in myocardial infarction.
aonly for unstable angina and NSTEMI.
bNumber of packs per day multiplied with years of smoking.
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Table 3 Multivariate analyses therapeutic decision (BMS vs DES)
Bivariate analyses (OR) Multivariate analyses (OR) p value*
Total population (n = 442)
Number of diseased vessels
1 0.520 0.560 0.006
> 1 Ref
NYHA class
NYHA class I Ref
NYHA class II 1.478
NYHA class III + IV 5.311
Hospital
1 0.565
2 1.016
3 45.176
4 Ref
Diabetes (yes vs no) 8.680 8.318 p < 0.001
Renal artery disease (yes vs no) 0.368
Current smoker (yes vs no) 0.599
Previous MI (yes vs no) 1.486
PVD (yes vs no) 1.017
Previous PTCA (yes vs no) 2.045
TIMI scorea
1 Ref
2 1.20
3 0.37
4 2.000
5 0.600
6 + 7 646189937
Constant 1.911 p < 0.001
Nagelkerke R2 16 %
Stable CAD (n = 358) Bivariate analyses (OR) Multivariate analyses (OR) p value*
BMI (kg/m2) 1.049
Hospital
1 0.578 0.466 0.013
2 1.034 1.047 0.884
3 26.671 29.381 0.001
4 Ref Ref
Previous MI (yes vs no) 1.513
NYHA class
NYHA class I Ref
NYHA class II 1.280
NYHA class III + IV 4.319
Number of diseased vessels
1 0.536
> 1 Ref
Current smoker (yes vs no) 0.588 0.404 0.014
Diabetes (yes vs no) 8.454 12.001 p < 0.001
Previous PTCA (yes vs no) 2.103 2.284 0.003
Constant 1.207 0.397
Nagelkerke R2 33 %
Unstable CAD (n = 84) Bivariate analyses (OR) Multivariate analyses (OR) p value*
Hospital
1 0.686
2 1.000
3 1346229036
4 Ref
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is possible that factors that are of predictive value were not 
included. Furthermore, the underlying reason why the treat-
ing hospital is associated with stent choice is unknown. This 
could be due to the operator (e.g. experience), for which 
data were not available for our analyses, or the availability 
and supply of resources might explain the association with 
the treating hospital, even though the Netherlands has a cen-
trally publicly funded healthcare system.
We were not able to compare patients treated solely with 
BMS and patients treated solely with DES. Stent choice 
for DES was defined as a PCI with at least one DES which 
includes patients treated with only DES but also patients 
treated with DES in combination with BMS, drug-eluting 
balloon angioplasty or standard balloon angioplasty. Conse-
quently, the associations that we have found actually explain 
why some patients receive DES and why other patients did 
not receive DES.
In addition, this study did not take into consideration the 
differences in stent choice (different types of DES) despite 
variation in their effectiveness. For example, the newer 
ultra-thin strut BMS leads to less restenosis than the thicker 
strut BMS; a study using the SOLSTICE registry showed 
that ultra-thin strut BMS leads to low 6-month major 
adverse cardiac event rates (5.8 %), including target lesion 
revascularisations [24]. Furthermore, we made no distinc-
tion between the types of drug coating (e.g. paclitaxel, siro-
limus, or everolimus) used for DES, even though this may 
affect clinical outcomes.
Lastly, the latest guideline on myocardial revascularisa-
tion [25] concluded that the newer generation DES have 
improved safety outcomes including death, MI and stent 
thrombosis compared with early-generation DES and BMS. 
Patients receiving DES have a lower risk of target lesion 
revascularisation than patients treated with BMS [3]. How-
ever, there is some concern of late stent thrombosis that may 
occur more frequently after DES than BMS [3]. Besides the 
implications of treatment variation on the effectiveness, it 
is also important to consider the costs. While BMS is less 
expensive than DES, BMS leads to more reinterventions 
than DES. Several studies have estimated the cost-effec-
tiveness of DES versus BMS and many of these studies 
concluded that initial DES treatment was overall more 
expensive than the BMS strategy [12–23]; the reduction in 
reinterventions did not offset the initial higher stent costs. 
In most of the studies DES was slightly more effective [12–
23] often leading to an incremental cost-effectiveness ratio 
that could not be considered cost-effective [13, 14, 17, 18, 
23]. However, some specific subgroups (diabetes, complex 
lesions, complex vessels, multi-vessel disease, or a combi-
nation of these risk factors) were identified in which DES 
resulted in a higher health gain in terms of quality-adjusted 
life-years compared with subgroups that were not at high 
risk of restenosis and complications. Consequently, in these 
subgroups, DES was considered more cost-effective. In our 
study some of these specific subgroups were also associated 
with a more frequent use of DES.
Limitations
The factors examined in the analyses explained 13–33 % 
of the variation in treatment decisions. While the treating 
hospital was associated with stent choice, it is possible that 
hospital is a proxy for a pre-existing patient case mix. Many 
clinical factors were included in the regression models but it 
Table 3 (continued)
Bivariate analyses (OR) Multivariate analyses (OR) p value*
NYHA class
NYHA class I Ref
NYHA class II 1105324892
NYHA class III + IV 8.895
Diabetes (yes vs no) 10.146 10.146 0.029
TIMI scorea
1 Ref
2 1.600
3 0.369
4 1.900
5 0.600
6 + 7 646189937
SBP (mmHg) 1.007
Constant 1.577 0.069
Nagelkerke R2 13 %
SBP systolic blood pressure, BMI body mass index, NYHA New York heart association, PTCA percutaneous transluminal coronary angioplasty, 
TIMI Thrombolysis In Myocardial Infarction.
aP value of multivariate analyses.
*p = 0.05
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paclitaxel-eluting stent in the Swedish healthcare system. Scand 
Cardiovasc J. 2006;40:17–24.
16. Goeree R, Bowen JM, Blackhouse G, et al. Economic evaluation 
of drug-eluting stents compared with bare metal stents using a 
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Economic evaluation of drug-eluting stents: a systematic literature 
review and model-based cost-utility analysis. Int J Technol Assess 
Healthcare. 2007;23:473–9.
During this study, this guideline was not available and thus 
it is possible that stent choice might have been somewhat 
different if the new guidelines had been applicable; DES 
could be more frequently used. Furthermore, we did not 
focus on fully bioresorbable stents, which have promising 
clinical outcomes since they provide desirable transient ves-
sel support without compromising the restoration of normal 
vessel biology, vessel imaging or treatment options in the 
long run [26]. Consequently, the stents evaluated in the Cir-
culating Cells cohort may not reflect the stent choices that 
will be made in the near future.
Recommendations
This study showed the existence of treatment variation across 
hospitals that may have an impact on long-term outcomes. 
It would be interesting to investigate if the treatment varia-
tion seen in this cohort will actually lead to differences in 
long-term outcomes and costs, which could be achieved by 
increasing the follow-up period. Van der Sijde et al. [27] have 
also emphasised the role of clinical observations to determine 
the most appropriate indication for specific types of stents.
Conclusions
This study showed that several clinical factors were associ-
ated with stent choice (DES or BMS) for CAD treatment, 
including diabetes, smoking, NYHA class, multi-vessel dis-
ease and previous PCI. In general, it appears that patients 
receive the most optimal stent given their clinical character-
istics. After correcting for the clinical factors, stent choice 
was also associated with the treating hospital probably due 
to operator variation and the availability and supply of spe-
cific stent types. These differences may lead differences in 
long term outcomes.
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